Platelet Membrane Assay for Factor VIII Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring Factor VIII activity in hemophilia A diagnosis and treatment monitoring are unreliable due to the use of phospholipid vesicles with high phosphatidylserine concentrations, which are not physiologically relevant and can be affected by anti-Factor VIII antibodies, leading to inaccurate results.
Innovation Solution
The use of platelet membrane-comprising compositions that mimic physiological conditions, allowing for the binding of Factor VIII to fibrin or fibrinogen, and the detection of its activity in the presence of Factor IXa and Factor X, providing a more accurate measurement of Factor VIII activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If phospholipid vesicles with high phosphatidylserine concentration are used in current fVIII assays, then the assay can be performed with available reagents, but the measurement reliability is poor and predictive value is low
Solution Approach 1:
The patent changes the key parameter of the membrane composition from high phosphatidylserine concentration phospholipid vesicles to platelet membrane composition with physiologically relevant phospholipid ratios. This parameter change transforms the assay from using artificial reagents to using physiologically relevant materials, thereby improving measurement reliability and predictive value while maintaining assay feasibility
Solution Approach 2:
The patent creates a more accurate copy of the physiological environment by using platelet membrane compositions that naturally occur in the body rather than artificial phospholipid vesicles. This copying approach ensures the assay conditions better reflect in vivo conditions, improving the reliability of fVIII activity measurements
2Ease of operation
If phospholipid vesicles are used in standard fVIII assays, then the assay procedure is established and routine, but the results are affected by anti-fVIII antibodies and lack physiological relevance
Solution Approach 1:
The patent modifies the membrane composition parameter from artificial phospholipid vesicles to platelet membrane compositions, which changes the binding characteristics of fVIII and reduces interference from anti-fVIII antibodies. This parameter change improves diagnostic accuracy while the assay procedure itself remains routine and established
Solution Approach 2:
The patent uses platelet membrane compositions that can be prepared fresh or obtained as disposable reagents, replacing the need for complex purification of native platelets. This approach maintains ease of operation while significantly improving measurement precision and physiological relevance
3Quantity of substance
If non-physiological agonists such as calcium ionophore are used to stimulate platelets, then many fVIII binding sites are exposed on platelet surface, but the conditions are not physiologically relevant
Solution Approach 1:
The patent inverts the approach by not using chemical agonists to force binding site exposure, but rather using physiologically activated platelets (thrombin-activated or spontaneously activated) that naturally expose binding sites under conditions that mimic in vivo physiology. This inversion achieves both binding site exposure and physiological relevance
4Reliability
If platelets are used to provide fVIII binding sites, then physiological conditions are mimicked, but the device complexity increases
Solution Approach 1:
The patent extracts the essential functional component (platelet membrane composition providing fVIII binding sites) from the complex whole platelet system. By using platelet membrane fractions or compositions rather than intact platelets, the assay maintains physiological relevance while reducing complexity in terms of platelet isolation and handling requirements
Solution Approach 2:
The patent introduces platelet membrane composition as an intermediary material that mediates between the artificial assay environment and physiological conditions. This intermediary provides the necessary binding sites and physiological context without requiring the full complexity of live platelet systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the reliability of Factor VIII activity measurement, improving diagnostic accuracy and therapeutic monitoring, especially in individuals with anti-Factor VIII antibodies, by using physiologically relevant binding sites on thrombin-activated platelets or platelet membrane fractions.
Implementation Method 1
contacting a sample in which Factor VIII (fVIII) is to be measured with fibrin or fibrinogen (fibrin(ogen)) and a platelet membrane-comprising composition, under conditions that permit binding of fibrin(ogen) to the platelet membrane-comprising composition and permit binding of fVIII in the sample to the fibrin(ogen)
Data Source
AI summary
The methods and compositions described herein relate to the measurement of factor VIII (fVIII) levels and/or activity.